Verona Pharma To Present Additional Analyses Of Phase 3 ENHANCE Studies In COPD At ATS 2024
Verona Pharma To Present Additional Analyses Of Phase 3 ENHANCE Studies In COPD At ATS 2024
維羅納製藥將在2024年的ATS上公佈對慢性阻塞性肺病3期增強研究的更多分析
PDUFA Target Action Date of June 26, 2024
Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4
PDUFA 的目標行動日期爲 2024 年 6 月 26 日
包括兩份口頭陳述在內的八張海報支持了ensifentrine的潛力,ensifentrine是一種正在研究的、同類首創的PDE3和PDE4的選擇性雙重抑制劑